Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058783 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 328
- Enrollment target
NCT03058783: Completed Phase 3 study, sponsored by Bausch Health Americas.
NCT03058783 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 328 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03058783, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 328 participants
- Enrollment target
Study Summary
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
Primary Outcome
Investigator Global Assessment (IGA) was determined based on evaluator-blinded evaluations of the inflammatory signs of atopic dermatitis. Evaluations were scored using a 5-point scale from clear (0) to severe (4), with higher numbers indicating worse scores.
Interventions
- DRUG IDP-124 Lotion
- DRUG IDP-124 Vehicle Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2020-05-12 |
| Phase | Phase 3 |
What the finished NCT03058783 record still lists
NCT03058783 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which IDP-124 Lotion is the first listed.
NCT03058783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03058783 about?
NCT03058783 is a clinical study titled "Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects". Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
What is the current status of trial NCT03058783?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 328 participants. The study started on 2018-08-14. Estimated completion is 2020-05-12.
What interventions are being tested in trial NCT03058783?
The interventions under investigation include: IDP-124 Lotion (DRUG), IDP-124 Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT03058783?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03058783's enrollment target sits among peer trials
328 1074th of 2000 higher than 926 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI